Replies to post #11451 on RespireRx Pharmaceuticals Inc (fka RSPI)

[enemem]

>>RD and analgesia. The fact that opioid receptors can influence respiratory function 'downstream' does not mean it has to be a two-way street. The receptors CX717 hits for RD are not opioid receptors, and the animal studies showed no effect on analgesia. We can't be sure that is the same in humans yet, but downstream interventions do not necessarily affect upstream processes.

I didn't mean to imply that ampakines work on opioid receptors. Neurons involved in espiratory rhythm generation express opioid receptors, and their depression is a direct (not downstream) effect of opioid administration. They also express AMPA receptors, which is why this depression is reversed by ampakines.
Afferent pathways (at least with respect to these two receptor types) are analogous. So if ampakines rescue respiration, I don't see why they wouldn't also reduce analgesia.

[bladerunner1717]

Neuro,

Great post. Thanks for your thoughts.

My question is about your last comment on Schering: Doesn't that take us right back into Psychiatry's fiefdom? I'm wondering--along with gfp, I'm sure--whether, given what's taken place with CX717, Psychiatry would now require even more toxicology studies for whatever molecules are in development over at Organon/Schering, before allowing further trials. Do you (or Davidal) have any sense if Organon's scientists were at all concerned by the findings that turned up with CX717? Do we know for certain that the drugs at Organon underwent the same kind of rigorous screening that CX717 has been subjected to?

I think I understand your concerns aobut narcolepsy/EDS, but given the limited number of options open to COR, doesn't this indication make the most sense for CX701? After all, we do have some clinical data in this indication, and COR can learn from the DARPA failures how to (not) construct the trials. Even CX717 could be tried here again, but with a better trial design.

Does Tran's previous employment at Lilly point to the possibility of a thawing of relations between Lilly and COR? Any sense of why Tran left Lilly? A cursory look at Tran's resume and writings suggest that he was a much better fit for Lilly than he was for Xenoport, at least in terms of clinical development. (Of course, maybe he just wanted to work in a different type environment.) Does Tran's work in schizophrenia and depression give any indication that COR might have something planned in those areas?


Bladerunner

[DewDiligence]

Point taken that all companies have abandoned MCI.

The intent of the post cited by Aiming was to focus on COR’s prospects in RD. Although there’s a plausible explanation for each failure and switched indication in COR’s past programs, the series of failures and switched indications makes me more skeptical of the prospects in RD than I otherwise would be.

That COR only recently discovered the RD indication adds to my skepticism.

Some posters on this board have stated that the RD indication is an outright scam. I don’t think that, but I do think the newfound emphasis on RD may be an example of Zebra’s Law. Regards, Dew

p.s. Regrettably, it looks like Wakefield is pitching after all. It’s too bad that baseball managers find it difficult to manage in a way that maximizes their teams’ winning chances.